Sebastiaan Verboeket, MD, PhD

epartment of Research and Jellinek, Arkin Mental Health Care, Amsterdam, University of Amsterdam, Amsterdam, The Netherlands

  • 1Article
  • 2025Active
  • 7Collaborators

About

Sebastiaan Verboeket, MD, PhD is affiliated with epartment of Research and Jellinek, Arkin Mental Health Care, Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. Sebastiaan Verboeket has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2025. Their work focuses on Catatonia.

Publications

JCP
Treatment with (Es)ketamine in Catatonia: A Systematic Review of Case Reports
Brief Report

Treatment with (Es)ketamine in Catatonia: A Systematic Review of Case Reports

October 13, 2025

Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to evaluate the efficacy and safety of ketamine and...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe